Nivolumab Market Forecasts Indicate Robust Growth Driven by Advances in Cancer Immunotherapy and Increased Global Access to Care
February 15, 2024 14:57 ET
|
Research and Markets
Dublin, Feb. 15, 2024 (GLOBE NEWSWIRE) -- The "Nivolumab Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. Recent advancements in cancer treatment and the...
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
January 16, 2024 17:01 ET
|
Adagene Inc.
- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and...
Ipilimumab + nivolumab Drug Insight and Market Forecast - 2032
December 14, 2023 10:08 ET
|
Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Ipilimumab + nivolumab Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides...
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update
August 31, 2023 07:32 ET
|
Adagene Inc.
- Best-in-class anti-CTLA-4 candidates designed for more than 30-fold increase in therapeutic index, addressing patient populations where CTLA-4-mediated Treg depletion is essential for efficacy – -...
7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding
May 22, 2023 13:05 ET
|
7 Hills Pharma
HOUSTON, May 22, 2023 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”) announced today that it has been awarded $13.5MM in nondilutive grant funds from the Cancer Prevention &...
Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update
March 28, 2023 16:30 ET
|
Adagene Inc.
- Clinical data for wholly-owned anti-CTLA-4 franchise show best-in-class safety profiles for unmasked and masked candidates, unlocking the full therapeutic benefit of anti-CTLA-4 in combination with...
Global Squamous Non-Small Cell Lung Cancer Market Report 2021-2031: Marketed, Clinical and Preclinical Molecules Available/Being Developed
October 22, 2021 04:58 ET
|
Research and Markets
Dublin, Oct. 22, 2021 (GLOBE NEWSWIRE) -- The "Squamous Non-Small Cell Lung Cancer: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031" report has been added to...
Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma
March 18, 2021 16:15 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., March 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today is announcing that ILLUMINATE-301, the Company’s pivotal registration trial of...
Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 Million
December 15, 2020 08:05 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the closing of a second tranche under its April 7, 2020, securities purchase agreement (the...
Global Programmed Death-Ligand 1 (PD-L1) Non-Small Cell Lung Cancer (NSCLC) Market Insights, Epidemiology and Market Forecast 20202030
October 09, 2020 04:24 ET
|
Research and Markets
Dublin, Oct. 09, 2020 (GLOBE NEWSWIRE) -- The "Programmed Death-Ligand 1 (PD-L1) Non-Small Cell Lung Cancer (NSCLC)-Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been...